Edwards Lifesciences (NYSE:EW) Stock Rating Upgraded by Barclays

Key Points

• Barclays upgraded Edwards Lifesciences to “strong buy,” while the broader analyst consensus remains “moderate buy” with an average price target of $100.27.
• Edwards reported quarterly earnings of $0.78 per share, exceeding estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion.
• The stock opened at $85.62, down 1.0%, with a market capitalization of approximately $49.3 billion; institutional investors own 79.46% of outstanding shares.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by analysts at Barclays to a "strong-buy" rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Saturday, September 26th. Piper Sandler reiterated an "overweight" rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Finally, Truist Financial boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Trading Down 1.0%

NYSE EW opened at $85.62 on Wednesday. The stock has a market capitalization of $49.30 billion, a price-to-earnings ratio of 49.21, a PEG ratio of 2.27 and a beta of 0.87. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business's fifty day moving average is $88.79 and its 200-day moving average is $86.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts predict that Edwards Lifesciences will post 3 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andrew M. Dahl sold 544 shares of the firm's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company's stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 5,045 shares of company stock valued at $455,341. Company insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rehmann Capital Advisory Group lifted its stake in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after buying an additional 130 shares during the last quarter. NorthRock Partners LLC grew its stake in Edwards Lifesciences by 1.0% in the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company's stock valued at $1,465,000 after buying an additional 153 shares during the last quarter. Elevation Wealth Partners LLC grew its stake in Edwards Lifesciences by 24.8% in the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company's stock valued at $67,000 after buying an additional 155 shares during the last quarter. Premier Path Wealth Partners LLC raised its holdings in Edwards Lifesciences by 4.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company's stock worth $311,000 after acquiring an additional 162 shares during the period. Finally, Ferguson Wellman Capital Management Inc. raised its holdings in Edwards Lifesciences by 0.7% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 27,077 shares of the medical research company's stock worth $2,168,000 after acquiring an additional 185 shares during the period. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.